Biobeat Raises $50 Million in Series B to Launch Cuff-less 24-hour Blood Pressure Monitor

Some startups chase disruption. Biobeat Technologies just made it look inevitable.

Founded in 2016 by Arik Ben Ishay, Johanan May, and Israel Sarussi, Biobeat was born from a battlefield problem and turned into a global medtech revolution. When Arik Ben Ishay served as a volunteer paramedic during the 2014 Israel-Gaza conflict, he faced a brutal truth: monitoring multiple patients meant juggling wires, cuffs, and chaos. Out of that chaos came clarity: what if one device could track everything, continuously, no cuffs, no limits? Fast-forward to today, and that idea just pulled in a $50 million Series B round backed by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical Technologies, with a strategic investor quietly adding fuel to the fire.

This isn’t your everyday wearable. Biobeat built the world’s first FDA-cleared cuff-less blood pressure monitoring system that reads 13 vital signs in real time. Their reflective photoplethysmography sensors don’t squeeze your arm; they decode your pulse with light. It’s science fiction that made it through peer review at Mayo Clinic, cleared by the FDA four times, and validated across skin tones and patient conditions. No cuff, no interruptions, just accuracy that would make a cardiologist smile.

The funding isn’t just capital; it’s combustion. It’s what will power Biobeat’s U.S. commercialization push out of Boca Raton, scaling a field sales team aimed straight at hospitals, cardiology groups, and telehealth providers ready to ditch the inconvenience of traditional monitoring. With partnerships already live at Mayo Clinic, Mount Sinai, Northwell Health, and Tampa General Hospital, Biobeat’s not testing theories; they’re rewriting clinical workflows in real time.

Credit where it’s due, the board’s now stacked with Steven Plachtyna from Ally Bridge, Dina Chaya, PhD, CFA from OrbiMed, and Evan Melrose, MD, MBA from Elevage. Add Raymond W. Cohen as Executive Chairman, and you’ve got a medtech dream team that’s collectively raised billions, sold companies to Boston Scientific, and knows exactly how to turn regulatory validation into market domination.

But here’s what makes this round different. This isn’t a bet on hype or health apps; it’s a bet on precision, prevention, and possibility. Biobeat’s tech gives hospitals data before the crisis, doctors insights before the symptom, and patients control before the condition. That’s the real story: the evolution from reactive medicine to predictive care, from the hospital room to the living room.